A randomized, phase 2 study evaluating the efficacy and safety of anakinra in the treatment of gout flares

In this Phase II study of patients with gout unsuitable for NSAIDs and colchicine (n=165), anakinra (100 or 200mg/day for 5 days) was comparable to triamcinolone (40mg single injection), both showing clinically meaningful reductions in patient-assessed pain intensity.

Arthritis & Rheumatology